Barclays Cuts Bristol Myers Price Target by 41%

Shares of Bristol Myers Squibb BMY are trading lower after Barclays cut the company from overweight to equal-weight and reduced the price target from $65 to $46.

Barclays is not a huge fan of the pharmaceutical industry as a whole right now, citing modest growth and pipelines that appear to be priced into valuations.

Lead analyst Mark Purcell commented on the call, “BMY's leadership is being challenged in an increasingly competitive immunoncology space as competitors broaden their portfolios and development programs.”

Related: Canadian Solar Gaps Higher On Canaccord Initiation

Barclays’ price target, which was derived with a DCF model, is inline with the market price. Purcell writes, “BMY shares appear fully valued in the absence of corporate activity or an incremental change in the outlook for I/O.”

Briston Myers Squibb shares were last trading down 0.9 percent shortly after Wednesday’s open.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesPrice TargetAnalyst RatingsBarclaysMark Purcell
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!